Effects of magnesium sulfate on lipid peroxidation and blood pressure regulators in preeclampsia

被引:39
作者
Ariza, AC
Bobadilla, N
Fernández, C
Muñoz-Fuentes, RM
Larrea, F
Halhali, A
机构
[1] Inst Nacl Nutr Salvador Zubiran, Dept Reprod Biol, Mexico City 14000, DF, Mexico
[2] Inst Nacl Nutr Salvador Zubiran, Dept Nephrol, Mexico City 14000, DF, Mexico
[3] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Mexico City, DF, Mexico
[4] Inst Nacl Nutr Salvador Zubiran, Dept Gastroenterol, Mexico City 14000, DF, Mexico
[5] Univ Iberoamer, Dept Hlth, Mexico City, DF, Mexico
关键词
magnesium sulfate; lipid peroxidation; ET-1; NO; CGRP; preeclampsia;
D O I
10.1016/j.clinbiochem.2004.09.018
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: To investigate the status of lipid peroxidation and serum levels of several vasoactive substances in preeclamptic (PE) pregnant women before and during treatment with magnesium sulfate (MgSO4). Design and methods: The study population included 16 PE women. Circulating levels of malondialdehyde (NIDA), endothelin 1 (ET-1), nitric oxide (NO) metabolites, and calcitonin gene-related peptide (CGRP) were measured before (at admission) and during MgSO4 treatment (at delivery and 24 h postpartum). Results: At admission systolic and diastolic blood pressures were 157 +/- 3 mm Hg and 106 +/- 2 mm Hg, respectively, and decreased significantly during treatment at delivery and 24 h postpartum (P < 0.0001). Before treatment, serum MDA concentrations were 0.383 +/- 0.037 mumol/L, and decreased significantly during MgSO4 administration at delivery and 24 h postpartum (P < 0.0001). In contrast, serum ET-1 levels at 24 h postpartum were significantly higher as compared with those observed before treatment (79 +/- 3 versus 65 +/- 2 pg/mL, P = 0.002). Serum NO metabolite concentrations were 26 +/- 3 mumol/L, and no significant changes were observed during treatment. Serum levels of CGRP were 50 +/- 3 pg/mL at admission, and increased significantly at partum (P < 0.001). Serum ET-1 correlated negatively with NO metabolites before treatment (r = -0.69, P = 0.002), but not during treatment. In contrast, ET-1 correlated positively with serum CGRP levels during treatment (r = 0.73, P = 0.002 and r = 0.71, P = 0.002, at delivery and 24 h postpartum, respectively), but not before treatment. Conclusions: This study demonstrates that MgSO4 administration to PE pregnant women induced significant changes in lipid peroxidation, production of ET-1 and CGRP. (C) 2004 The Canadian Society of Clinical Chemists. All rights reserved.
引用
收藏
页码:128 / 133
页数:6
相关论文
共 28 条
[1]   Effects of magnesium sulfate on tissue lactate and malondialdehyde levels after cerebral ischemia [J].
Bariskaner, H ;
Ustun, ME ;
Ak, A ;
Yosunkaya, A ;
Ulusoy, HB ;
Gurbilek, M .
PHARMACOLOGY, 2003, 68 (03) :162-168
[2]   EFFECTS OF MAGNESIUM-SULFATE TREATMENT ON PERINATAL CALCIUM-METABOLISM .1. MATERNAL AND FETAL RESPONSES [J].
CRUIKSHANK, DP ;
PITKIN, RM ;
REYNOLDS, WA ;
WILLIAMS, GA ;
HARGIS, GK .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1979, 134 (03) :243-249
[3]  
DAVIDGE ST, 1992, OBSTET GYNECOL, V79, P897
[4]   Magnesium reduces free radicals in an in vivo coronary occlusion-reperfusion model [J].
Garcia, LA ;
Dejong, SC ;
Martin, SM ;
Smith, RS ;
Buettner, GR ;
Kerber, RE .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (02) :536-539
[5]   Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy [J].
Gifford, RW ;
August, PA ;
Cunningham, G ;
Green, LA ;
Lindheimer, MD ;
McNellis, D ;
Roberts, JM ;
Sibai, BM ;
Taler, SJ .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2000, 183 (01) :S1-S22
[6]   Calcitonin gene- and parathyroid hormone-related peptides in preeclampsia: Effects of magnesium sulfate [J].
Halhali, A ;
Wimalawansa, SJ ;
Berentsen, V ;
Avila, E ;
Thota, CS ;
Larrea, F .
OBSTETRICS AND GYNECOLOGY, 2001, 97 (06) :893-897
[7]  
Hans CP, 2003, MAGNESIUM RES, V16, P13
[8]   Oxidative stress in the pathogenesis of preeclampsia [J].
Hubel, CA .
PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, 1999, 222 (03) :222-235
[9]  
Kharb S, 2000, J Assoc Physicians India, V48, P956
[10]  
Luo WB, 2002, ACTA PHARMACOL SIN, V23, P930